Initial sulfonylurea use and subsequent insulin therapy in older subjects with type 2 diabetes mellitus

Diabetes Therapy

Volumn 3, Issue 1, 2012, Pages 1-9

  Fu, Alex Z ^a   Qiu, Ying ^b   Davies, Michael J ^b   Engel, Samuel S ^b  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Elderly; Insulin therapy; Metformin; Sulfonylurea; Type 2 diabetes

Indexed keywords

INSULIN; METFORMIN; SULFONYLUREA;

AGED; ARTICLE; BODY MASS; COHORT ANALYSIS; DISEASE ASSOCIATION; DRUG EFFECT; ELDERLY CARE; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; TREND STUDY;

EID: 84871128672     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-012-0012-9     Document Type: Article

References (23)

1. UK Prospective Diabetes Atudy 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes. 1995;44:1249-58.
2. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281:2005-12.
3. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA. 2002;287: 360-72.
4. Kahn SE, Haffner SM, Heise MA, ADOPT Study Group, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427-43.
5. Kahn SE, Lachin JM, Zinman B, ADOPT Study Group, et al. Effects of rosiglitazone, glyburide, and metformin on beta-cell function and insulin sensitivity in ADOPT. Diabetes. 2011;60:1552-60.
6. Gong Z, Muzumdar RH. Pancreatic function, type 2 diabetes, and metabolism in aging. Int J Endocrinol. 2012;2012:320482.
7. Zhang Q, Rajagopalan S, Marrett E, Davies MJ, Radican L, Engel SS. Time to treatment initiation with oral antihyperglycaemic therapy in US patients with newly diagnosed type 2 diabetes. Diabetes Obes Metab. 2012;14:149-54.
8. Sinclair AJ, Alexander CM, Davies MJ, Zhao C, Mavros P. Factors associated with initiation of antihyperglycaemic medication in UK patients with newly diagnosed type 2 diabetes. BMC Endocr Disord. 2012;12:1.
9. Riedel AA, Heien H, Wogen J, Plauschinat CA. Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy. Pharmacotherapy. 2007;27:1102-10.
10. Lobo FS, Wagner S, Gross CR, Schommer JC. Addressing the issue of channeling bias in observational studies with propensity scores analysis. Res Social Adm Pharm. 2006;2:143-51.
11. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41-55.
12. Parsons LS. Reducing bias in a propensity score matched-pair sample using greedy matching techniques (paper 214-26). Paper presented at: SUGI 26 Proceedings (Proceedings of the 26th annual SAS users group international conference), Long Beach, CA, April 22-25, 2001; Cary, NC.
13. Perez N, Moisan J, Sirois C, Poirier P, Gregoire JP. Initiation of insulin therapy in elderly patients taking oral antidiabetes drugs. Can Med Assoc J. 2009;180:1310-6.
14. Ringborg A, Lindgren P, Yin DD, Martinell M, Stalhammar J. Time to insulin treatment and factors associated with insulin prescription in Swedish patients with type 2 diabetes. Diabetes Metab. 2010;36:198-203.
15. Kostev K, Dippel FW. Predictors for the initiation of a basal supported oral therapy (BOT) in type 2 diabetic patients under real-life conditions in Germany. Prim Care Diabetes. 2012 (Epub ahead of print).
16. Donnan PT, Steinke DT, Newton RW, Morris AD. Changes in treatment after the start of oral hypoglycaemic therapy in type 2 diabetes: a population-based study. Diabet Med. 2002;19: 606-10.
17. Eurich DT, Simpson SH, Majumdar SR, Johnson JA. Secondary failure rates associated with metformin and sulfonylurea therapy for type 2 diabetes mellitus. Pharmacotherapy. 2005;25:810-6.
18. Cook MN, Girman CJ, Stein PP, Alexander CM. Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with type 2 diabetes in UK primary care. Diabet Med. 2007;24:350-8.
19. Rustenbeck I. Desensitization of insulin secretion. Biochem Pharmacol. 2002;63:1921-35.
20. Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY. Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab. 2005;90:501-6.
21. Takahashi A, Nagashima K, Hamasaki A, et al. Sulfonylurea and glinide reduce insulin content, functional expression of K(ATP) channels, and accelerate apoptotic beta-cell death in the chronic phase. Diabetes Res Clin Pract. 2007;77:343-50.
22. Kim JY, Lim DM, Park HS, et al. Exendin-4 protects against sulfonylurea-induced beta-cell apoptosis. J Pharmacol Sci. 2012;118:65-74.
23. Satoh J, Takahashi K, Takizawa Y, et al. Secondary sulfonylurea failure: comparison of period until insulin treatment between diabetic patients treated with gliclazide and glibenclamide. Diabetes Res Clin Pract. 2005;70:291-7.